Absci’s big moment The entry into Phase I trials of a de novo generative AI drug by Absci is something of a landmark. It’s a promising start to a very long journey. “We’re excited to become a clinical-stage biotech company,” says McClain. “It’s exciting from an AI drug

→ View original post on X — @tiernanraytech